LRP6, which has been previously discovered to share the same structures as LRP5, has also been associated with many cancer progressions such as human triple negative breast cancer (TNBC), primary chronic lymphocytic leukemia (CLL), nonsmall cell lung cancer (NSCL), lung squamous cell carcinoma (LSCC), and hepatocellular carcinoma (HCC).
The knockdown of LRP5 or LRP6 decreased tumorigenesis <i>in vitro</i> and <i>in vivo</i>, identifying both receptors as potential treatment targets in TNBC.